Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
Retrieved on:
Wednesday, August 18, 2021
Cancer, CA9, Australian Securities Exchange, Hereditary lobular breast cancer, Food, Institute, PSMA, MRI, Lung, Breast cancer, Woman, Metastasis, German Cancer Research Center, Emory University, Lobular carcinoma, Winship Cancer Institute, DKFZ, Glutamate carboxypeptidase II, Squamous cell carcinoma, ILC, Zip, ASX, Prostate cancer, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Carbonic anhydrase, TLX, Diagnosis, TNBC, Triple-negative breast cancer, Disease, PET, Neck, HER2, Head, LinkedIn, Breast, FDA, Population, GLOBE, German Cancer Aid, TGA, Positron emission tomography, Breakthrough therapy, Kit, Temperature, Patient, CT, Heidelberg, NIH, GCPII, MTR, Kidney cancer, Pharmaceutical industry, Medical imaging, Medical device
Both TLX591-CDx and TLX250-CDx have potential utility in breast cancer imaging, particularly for specific phenotypes that are not consistently well imaged using existing techniques.
Key Points:
- Both TLX591-CDx and TLX250-CDx have potential utility in breast cancer imaging, particularly for specific phenotypes that are not consistently well imaged using existing techniques.
- Breast Cancer is the most commonly occurring cancer in women and the second most common cancer overall.7 In 2020, over 2.2 million women were diagnosed with breast cancer and 685,000 died from their disease.8
Lobular breast cancer (also called invasive lobular carcinoma) is atype of breast cancerthat begins in the milk-producing glands (lobules) of the breast. - It is the second most common type of breast cancer, accounting for 10-15% of all invasive breast cancers.
- Triple-negative breast cancer accounts for 10-15% of all breast cancers with the term triple-negative referring to the fact that the cancer cells do not have any of the three markers commonly found on breast cancer cells the oestrogen and progesterone receptors and HER2 protein.